|
|
Contact Pathway Activation on Vascular Devices |
| 2R01HL144113-05 |
|
NHLBI |
2022 |
|
|
Sarcoglycan in Myopathy and Muscle Membrane Stability |
| 5R01HL061322-23 |
|
NHLBI |
2022 |
|
|
Synthetic Mesenchymal Stem Cell Niches for Vascular Therapy |
| 5R01HL119371-09 |
|
NHLBI |
2022 |
|
|
Optimized Stents for the Femoropopliteal Artery |
| 5R01HL125736-08 |
|
NHLBI |
2022 |
|
|
Impaired Mitochondrial Energetics is a Driver of Hemodialysis Access Related Hand Dysfunction |
| 5R01HL148597-04 |
|
NHLBI |
2022 |
|
|
Molecular mechanisms regulating peripheral arterial disease pathobiology in chronic kidney disease |
| 5R01HL149704-03 |
|
NHLBI |
2022 |
|
|
Gut Microbiota and Cerebral Vascular Disease |
| 5R01HL150537-03 |
|
NHLBI |
2022 |
|
|
Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis. |
| 5R01HL151367-03 |
|
NHLBI |
2022 |
|
|
Combinatorial Approaches to Improved Blood-contacting Polymer Biomaterials |
| 5R01HL153231-03 |
|
NHLBI |
2022 |
|
|
Multifunctional VAD Technology for High-Risk Pediatric Patients |
| 5R01HL153536-03 |
|
NHLBI |
2022 |